Peers questioned whether NHS diagnosis rates, public awareness and trial capacity are strong enough for emerging dementia drugs, as the Government pointed to £555m in recent research funding, work to restore the 66.7% diagnosis target, a new frailty and dementia framework by year end, and NICE reviews of two Alzheimer’s treatments.